Capricor Therapeutics Inc遭受重挫。Piper Sandler今日宣布，将该公司股票评级由“增持”下调至“中性”。更令人震惊的是，其目标价被大幅削减——从原先的58美元骤降至仅2美元。这一调整幅度之大，引发市场广泛关注。
Capricor Therapeutics Inc遭受重挫。Piper Sandler今日宣布，将该公司股票评级由“增持”下调至“中性”。更令人震惊的是，其目标价被大幅削减——从原先的58美元骤降至仅2美元。这一调整幅度之大，引发市场广泛关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.